Treatment Of Newly Diagnosed, High-Grade, Malignant Glioma With Polifeprosan 20 Containing Carmustine Implant (Gliadel Wafer) Using MR Spectroscopy Data As A Primary Indicator Of Therapeutic Response.
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 07 May 2010
At a glance
- Drugs Carmustine polifeprosan 20 wafer (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms Gliadel-MRS
- 26 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Feb 2009 New trial record